Novo Holdings invests in biotech company for third time
![Naveed Siddiqi, board director of Amolyt and senior partner at Novo Holdings, says Amolyt "is a great example of a high quality, late stage private European company." | Photo: Novo Ventures / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/14816251/w3pnsr/ALTERNATES/schema-16_9/doc7ofd5cmslv52m9mehoz.jpg)
Novo Holdings has invested, for the third time, in French-American biotech company Amolyt pharma, which develops therapies against endocrine disorders, the investment company reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Holdings invests in US-based gene-editing company
For subscribers
Novo Holdings invests in Danish medtech firm
For subscribers